Ivo Abraham

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 59

Top Topics

Prostate Cancer

Systematic Review

Top Venues

Journal of medical economics

Expert review of pharmacoeconomics & outcomes research

Future oncology (London, England)

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer. Expert review of pharmacoeconomics & outcomes research 23 (3) (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment. Expert review of pharmacoeconomics & outcomes research 23 (3) (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer. Expert review of pharmacoeconomics & outcomes research 23 (3) (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert review of pharmacoeconomics & outcomes research 23 (3) (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert review of pharmacoeconomics & outcomes research (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment. Expert review of pharmacoeconomics & outcomes research (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
The economic value of knowing BRCA status : BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer. Expert review of pharmacoeconomics & outcomes research (2023)
Hala H Halawah, Nimer S Alkhatib, Abdulaali R Almutairi, Mohammad Saleh, Shiraz S Halloush, Omar Rashdan, Lama Masadh, Osama H Abusara, Ivo Abraham
Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan. Journal of medical economics (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment. Expert review of pharmacoeconomics & outcomes research (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert review of pharmacoeconomics & outcomes research (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment. Expert review of pharmacoeconomics & outcomes research 23 (3) (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment. Expert review of pharmacoeconomics & outcomes research 23 (3) (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer. Expert review of pharmacoeconomics & outcomes research 23 (3) (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer. Expert review of pharmacoeconomics & outcomes research (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert review of pharmacoeconomics & outcomes research 23 (3) (2023)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter, Ivo Abraham
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert review of pharmacoeconomics & outcomes research 23 (3) (2023)
Shiraz Halloush, Nimer S Alkhatib, Abdulaali R Almutairi, Mathias Calamia, Hala Halawah, Mavis Obeng-Kusi, Martin Hoyle, Omar Rashdan, Jim Koeller, Ivo Abraham
Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective. The Annals of pharmacotherapy (2023)
Rebecca M Thiede, Mohammad Fazel, Karen M MacDonald, Ivo Abraham
Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria? Expert opinion on pharmacotherapy 23 (14) (2022)
Lina H AlLehaibi, Mukhtar Alomar, Abdulaziz Almulhim, Sarah Al-Makki, Nazar R Alrwaili, Shahad Al-Bassam, Semat Alsultan, Jenan Al Saeed, Mohammad Alsheef, Ivo Abraham, Ahmed A Alamer
Effectiveness and Safety of Enoxaparin Versus Unfractionated Heparin as Thromboprophylaxis in Hospitalized COVID-19 Patients: Real-World Evidence. The Annals of pharmacotherapy (2022)
Daniel Arku, Consuela Yousef, Ivo Abraham
Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning. Expert opinion on drug safety 21 (10) (2022)
Yahya A Mohzari, Ahmed A Alamer, Majda Alattas, Ahmed A Alrashed, Nura A Alshehab, Turkiah K Alkhaldi, Amnah A Alamer, Syed Mohammed Basheeruddin Asdaq, Doaa Aljefri, Hamdan N Alajami, Yazed Saleh Alsowaida, Maya Mathew, Mohammed I AlMusawa, Mukhtar Alomar, Raghad Y Alharbi, Malik Khuwaja, Reem F Bamogaddam, Ashwaq H Alharthi, Aisha Y Faqihi, Bashayer F Alrumayyan, Abeer Alshareef, Batool M Alhassan, Nader Y Damfu, Ghada S Alajmi, Asma Albujaidy, Maram Alghalbi, Saleh A Alajlan, Ivo Abraham, Abdulaziz Saleh Almulhim
Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence. Expert review of anti-infective therapy 20 (7) (2022)
Neda Alrawashdh, Jamie Vraney, Briana M Choi, Abdulaali R Almutairi, Ivo Abraham, Ali McBride
Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer. Future oncology (London, England) 18 (19) (2022)
Ahmed A Alamer, Ahmed A Alrashed, Mashael Alfaifi, Bandar Alosaimi, Fatimah AlHassar, Malak Almutairi, Jude Howaidi, Wedad Almutairi, Yahya Mohzari, Tarek Sulaiman, Ahmed Hamdan Al-Jedai, Hamdan N Alajami, Fatima Alkharji, Ali Alsaeed, Alaa H Alali, Abdullah A Baredhwan, Ivo Abraham, Abdulaziz Saleh Almulhim
Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Current medical research and opinion 37 (7) (2021)
Ali McBride, Karen M MacDonald, Adolfo Fuentes-Alburo, Ivo Abraham
Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. Journal of medical economics 24 (1) (2021)
Mohammad Fazel, Neda AlRawashdh, Ahmed A Alamer, Clara Curiel-Lewandrowski, Ivo Abraham
Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma. Expert opinion on biological therapy 21 (12) (2021)
Dina Hamarneh, Nimer S Alkhatib, Kris Denhaerynck, Stefaan Vancayzeele, Heidi Brié, Karen M MacDonald, Ivo Abraham
Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients. Current medical research and opinion 37 (3) (2021)
Briana M Choi, Rachel B Abraham, Hala Halawah, Matthias Calamia, Mavis Obeng-Kusi, Neda Alrawashdh, Daniel Arku, Ivo Abraham
Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities. Journal of medical economics 24 (sup1) (2021)
Nimer S Alkhatib, Nancy K Sweitzer, Christopher S Lee, Brian Erstad, Marion Slack, Mahdi Gharaibeh, Jason Karnes, Walter Klimecki, Kenneth Ramos, Ivo Abraham
Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. American journal of cardiovascular drugs : drugs, devices, and other interventions 21 (2) (2021)
Ali McBride, Neda Alrawashdh, Trace Bartels, Logan Moore, Daniel Persky, Ivo Abraham
Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy. Future oncology (London, England) 17 (26) (2021)
Ali McBride, Neda Alrawashdh, Karen M MacDonald, Ivo Abraham
Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients. Future oncology (London, England) (2021)
Ivo Abraham, Uchenna Onyekwere, Baris Deniz, Donald Moran, Marc Chioda, Karen M MacDonald, Huan Huang
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy. Journal of medical economics (2021)
Abdulaali R Almutairi, Brian L Erstad, Ali McBride, Marion Slack, Ivo Abraham
Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data. Expert opinion on drug safety 20 (4) (2021)
Karen M MacDonald, Neda Alrawashdh, Ali McBride, Ivo Abraham
Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. Future oncology (London, England) 17 (33) (2021)
Ali McBride, Karen M MacDonald, Adolfo Fuentes-Alburo, Ivo Abraham
Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. Journal of medical economics 24 (1) (2021)
Mavis Obeng-Kusi, Magdiel A Habila, Denise J Roe, Brian L Erstad, Ivo Abraham
Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries. Journal of medical economics 24 (sup1) (2021)
Nasser Alkhushaym, Abdulaali R Almutairi, Abdulhamid Althagafi, Saad B Fallatah, Mok Oh, Jennifer R Martin, Hani M Babiker, Ali McBride, Ivo Abraham
Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis. Expert opinion on drug safety 19 (3) (2020)
Lynh Nguyen, Xiaohui Zhang, Evans Roberts, Seongseok Yun, Kathy McGraw, Ivo Abraham, Jinming Song, Diana Braswell, Dahui Qin, David A Sallman, Jeffrey E Lancet, Alan F List, Lynn C Moscinski, Eric Padron, Ling Zhang
Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1. Leukemia & lymphoma 61 (6) (2020)
Nimer S Alkhatib, Ali McBride, Marion Slack, Sandipan Bhattacharjee, Brian Erstad, Kenneth Ramos, Ivo Abraham
Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs). Journal of medical economics 23 (11) (2020)
Anita M Leys, Eva Ramboer, Mérédis Favreau, Kris Denhaerynck, Karen M MacDonald, Ivo Abraham, Heidi Brié
Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study. Clinical ophthalmology (Auckland, N.Z.) 14 (2020)
Nimer S Alkhatib, Ivo Abraham
The six Delta platform for outcome-based contracting for pharmaceuticals. Journal of medical economics 23 (11) (2020)
Nimer S Alkhatib, Brian Erstad, Kenneth Ramos, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Ivo Abraham
Pricing methods in outcome-based contracting: δ3: reference-based pricing. Journal of medical economics 23 (11) (2020)
Ali McBride, Weijia Wang, Kim Campbell, Sanjeev Balu, Karen MacDonald, Ivo Abraham
Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. Journal of medical economics 23 (8) (2020)
Nimer S Alkhatib, Kenneth Ramos, Brian Erstad, Marion Slack, Ali McBride, Sandipan Bhattacharjee, Ivo Abraham
Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing. Journal of medical economics 23 (11) (2020)
Elisabeth H van Aken, Mérédis Favreau, Eva Ramboer, Kris Denhaerynck, Karen M MacDonald, Ivo Abraham, Heidi Brié
Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study). Clinical ophthalmology (Auckland, N.Z.) 14 (2020)
Nimer S Alkhatib, Marion Slack, Sandipan Bhattacharjee, Brian Erstad, Kenneth Ramos, Ali McBride, Ivo Abraham
Pricing methods in outcome-based contracting: δ6: adherence-based pricing. Journal of medical economics 23 (11) (2020)
Nimer S Alkhatib, Kenneth Ramos, Brian Erstad, Marion Slack, Ali McBride, Sandipan Bhattacharjee, Ivo Abraham
Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing. Journal of medical economics 23 (11) (2020)
Nimer S Alkhatib, Sandipan Bhattacharjee, Ali McBride, Kenneth Ramos, Marion Slack, Brian Erstad, Ivo Abraham
Pricing methods in outcome-based contracting: δ4: safety-based pricing. Journal of medical economics 23 (11) (2020)
Nimer S Alkhatib, Diana Sun, Kris Denhaerynck, Dina Hamarneh, Yoleen Van Camp, Lorenzo Villa, Heidi Brié, Stefaan Vancayzeele, Karen M MacDonald, Ivo Abraham
Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients. Current medical research and opinion 37 (1) (2020)
Nimer S Alkhatib, Ali McBride, Sandipan Bhattacharjee, Kenneth Ramos, Brian Erstad, Marion Slack, Dean Billheimer, Ivo Abraham
Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing. Journal of medical economics 23 (11) (2020)
Karen MacDonald, Ali McBride, Neda Alrawashdh, Ivo Abraham
Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv. Journal of medical economics 23 (12) (2020)
Kenneth M Faulkner, Karen M MacDonald, Ivo Abraham, Abdulaziz Alhossan, Christopher S Lee
'Real-world' effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert review of clinical immunology 17 (1) (2020)
Mahdi Gharaibeh, Ali McBride, David S Alberts, Marion Slack, Brian Erstad, Nimer Alsaid, J Lyle Bootman, Ivo Abraham
Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. PharmacoEconomics 36 (10) (2019)
Amit Algotar, Chiu-Hsieh Paul Hsu, H-H Sherry Chow, Shona Dougherty, Hani M Babiker, David G Marrero, Ivo Abraham, Rachit Kumar, Jennifer A Ligibel, Kerry S Courneya, Cynthia A Thomson
Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP): Protocol for a Feasibility and Exploratory Efficacy Study in Men on Androgen Deprivation Therapy. JMIR research protocols 8 (2) (2019)
Robert L Crocker, Jason T Hurwitz, Amy J Grizzle, Ivo Abraham, Rick Rehfeld, Randy Horwitz, Andrew T Weil, Victoria Maizes
Real-World Evidence from the Integrative Medicine Primary Care Trial (IMPACT): Assessing Patient-Reported Outcomes at Baseline and 12-Month Follow-Up. Evidence-based complementary and alternative medicine : eCAM 2019 (2019)
Karen M MacDonald, Abhishek Kavati, Benjamin Ortiz, Abdulaziz Alhossan, Christopher S Lee, Ivo Abraham
Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert review of clinical immunology 15 (5) (2019)
Mahdi Gharaibeh, Ali McBride, David S Alberts, Brian Erstad, Marion Slack, Nimer Alsaid, J Lyle Bootman, Ivo Abraham
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. PharmacoEconomics 36 (11) (2019)
Ivo Abraham, Razan Alsheikh, Karen MacDonald
A Cautionary Research Note on Standard Versus Extended Release Tacrolimus. Progress in transplantation (Aliso Viejo, Calif.) 29 (1) (2018)
Ivo Abraham
Letter to the Editor: When Claiming a U-shaped Association between Uric Acid Levels and Major Adverse Cardiac Events, Perhaps Show the Evidence? Journal of Korean medical science 33 (6) (2018)
Noha Ashy, Thanh-Nga Nguyen, Kris Denhaerynck, Mahdi Gharaibeh, Abdulaziz Alhossan, Stefaan Vancayzeele, Heidi Brié, Ann Aerts, Karen M MacDonald, Ivo Abraham
Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients. International journal of chronic diseases 2017 (2017)